ArticleClinical case reports2025
Cyclic Thrombocytopenia Treated With Platelet Transfusion and Oral Preparation Containing Hyaluronic Acid (Oralvisc).
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyclic Thrombocytopenia Treated With Platelet Transfusion and Oral Preparation Containing Hyaluronic Acid (Oralvisc).Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic thrombocytopenia (CTP) is a rare disorder characterized by periodic platelet fluctuation with substantial amplitude from low to high. Currently, there are no standardized guidelines on treatment, and patients with CTP generally do not respond to standard ITP treatments, including corticosteroids, splenectomy, and intravenous immunoglobulin. We present a case of chronic CTP who failed multiple therapies used for immune thrombocytopenia but had resolution of muco-cutaneous bleeding with supportive platelet transfusion at platelet nadir. Eventually, the patient had normalization of the platelet count after she applied an oral preparation containing hyaluronic acid (Oralvisc) for concomitant osteoarthritis. The effect of Oralvisc on the platelet count retained after discontinuation of the drug. We suggest that supportive platelet transfusion at the nadir of thrombocytopenia is an effective management option in symptomatic patients. Anti-inflammatory medications, suppressing bradykinin and leptin, may be applied to alleviate platelet fluctuation and improve symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.